Studies alpha-synuclein and brain symptoms in smell loss
Part of Brain & nervous system, Ear, nose & throat clinical trials.
This study looks at whether a specific brain protein (alpha-synuclein) is linked to other neurologic symptoms in people who have long-lasting smell loss. It may help researchers understand what causes smell loss and how it relates to later brain or nerve changes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 55 and 75 years old
- Your smell loss has been slowly getting worse and does not come and go
- You can understand the study and agree to participate
- You can follow instructions for tests and visits
- You do not have dementia or Parkinson’s (or obvious signs of them)
- Your smell loss is not due to major nasal problems or certain causes like trauma, infections, surgery, or medicines that affect smell
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether daily smell training can improve smell loss caused by COVID-19. It may help people regain smell and possibly reduce related symptoms like distorted smells.
This study uses brain imaging and electrical recordings to understand the brain's role in smell loss from any cause—like COVID, sinus problems, or chemotherapy. You may be eligible if you have any degree of smell loss lasting under a year.
This study takes a small tissue sample from inside your nose to look for changes linked to Alzheimer's disease or smell problems. It may help us better understand how these conditions affect the brain.
This trial tests if smell training can improve smell loss and other non-motor symptoms in people with Parkinson's disease. If you have Parkinson's and a reduced sense of smell, this study may help you find a new way to manage symptoms.
This study tests whether a daily smell training routine can help improve your sense of smell. It is open to adults with any kind of smell loss or problem, including those with conditions like COVID-19 or head injury, but not certain brain diseases.
This trial uses remote, at-home (or remote) smell-based testing to help researchers assess health in people with preclinical Alzheimer’s disease and in control participants. It may help by showing how well smell-related changes can signal disease status over time.
Hear when a new Idiopathic Anosmia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.